Rxcurve
HCPCS Q0249 · per 1 MG

Tocilizumab for covid-19

Products billed under this code include Actemra IV.

Payment limit per 1 MG, by effective quarter, 2Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under Q0249

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Actemra IV Genentech, Inc 50242-0135-01 80 $605.52
Actemra IV Genentech, Inc 50242-0136-01 200 $1,513.80
Actemra IV Genentech, Inc 50242-0137-01 400 $3,027.60

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $7.569 $0.00 1 MG Tocilizumab for covid-19 v1, posted September 17, 2026
3Q26 $7.569 $0.00 1 MG Tocilizumab for covid-19 v1, posted September 15, 2026
2Q26 $7.569 $0.00 1 MG Tocilizumab for covid-19 v1, posted September 15, 2026
1Q26 $7.569 $0.00 1 MG Tocilizumab for covid-19 v1, posted September 15, 2026
4Q25 $7.569 $0.00 1 MG Tocilizumab for covid-19 v1, posted September 8, 2026
3Q25 $7.569 $0.00 1 MG Tocilizumab for covid-19 v1, posted March 10, 2026
2Q25 $7.569 $0.00 1 MG Tocilizumab for covid-19 v1, posted March 10, 2026
1Q25 $7.569 $0.00 1 MG Tocilizumab for COVID-19 v1, posted December 19, 2025
4Q24 $7.569 $0.00 1 MG Tocilizumab for COVID-19 v1, posted June 11, 2025
3Q24 $7.569 +$0.997 1 MG Tocilizumab for COVID-19 v1, posted June 11, 2025
2Q24 $6.572 – 1 MG Tocilizumab for COVID-19 v1, posted March 11, 2025

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files